Viswa Colluru, Enveda Biosciences CEO

'As the mar­ket has turned': Enve­da se­cures $68M to move re­vised pipeline in­to the clin­ic in 2023

Enve­da Bio­sciences will en­ter the clin­ic next year with at least one of its three main pro­grams thanks to a $68 mil­lion boost in fi­nanc­ing — about $55 mil­lion via eq­ui­ty and the re­main­der debt.

Found­ed by an ear­ly em­ploy­ee at AI start­up Re­cur­sion Phar­ma­ceu­ti­cals, Enve­da has ad­just­ed its pri­or­i­ties since dis­clos­ing a $51 mil­lion Se­ries A in June 2021. At the time, CEO Viswa Col­lu­ru told End­points News the three core ar­eas were Wil­son dis­ease, NASH and Parkin­son’s.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.